Abstract 5340: Novel small-molecule antagonists of the PD1/PD-L1 axis

Abstract

Abstract Immuno-therapy has become a leading strategy to fight cancer. Over the past few years, immuno-therapies using checkpoint inhibitor monoclonal antibodies (mAbs) against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) have demonstrated improved survival compared with chemotherapy. We describe the identification and characterization of an innovative series of synthetic compounds (named PyrDLones, patented) endowed with nanomolar activity against PD-L1. PyrDLones properties were characterized using several biophysical techniques including microscale thermophoresis (MST) and fluorescence resonance energy transfer (FRET) measurements. In vitro, selected small molecules demonstrate a high affinity for human PD-L1, potently disrupt the PD-L1:PD-1 interaction (<2nM), and inhibit Src homology region 2 domain-containing phosphatase (SHP2) recruitment to PD-1 (<4nM). As a result, upon binding to and inhibiting PD-L1, these molecules reactivate proliferation of CTL-L2 cells expressing PD-1 (EC50=44nM). More than 150 molecules have been synthesized and a dozen of highly potent “PD-L1 silencing compounds” have been identified, based on in vitro measurements. Structure-activity relationships have been defined and an in silico drug-target model supporting the mechanism of action has been built. Experiments are on-going to delineate further the molecular mechanism of action of the PyrDLones (drug-induced PD-L1 dimer formation), the cellular consequences of the PD-L1 silencing (reactivation of cytotoxic T cells in the tumor microenvironment) and to characterize their activity in vivo. In summary, we have discovered a novel series of potent, small molecule PD-L1 antagonists, amenable to the design of orally active drugs for immuno-therapy of cancers. Citation Format: Romain Magnez, Natascha Leleu-Chavain, Morgane Tardy, Hassiba El Bouazzati, Fréderique Klupsch, Christian Bailly, Régis Millet, Bruno Quesnel, Xavier Thuru. Novel small-molecule antagonists of the PD1/PD-L1 axis [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5340.